Drug Profile
VRC CHKVLP059 00 VP
Alternative Names: Alum-adjuvanted chikungunya virus-like particle vaccine; Chikungunya virus virus-like particle vaccine; Chikungunya-virus-vaccine-VRC; CHIKV-VLP; PXVX 0317; VRC-CHKVLP059-00-VPLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer Bavarian Nordic; Emergent BioSolutions; National Institute of Allergy and Infectious Diseases; Walter Reed Army Institute of Research
- Class Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chikungunya virus infections
Most Recent Events
- 23 Feb 2024 Bavarian Nordic announces intention to submit Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Chikungunya virus infections in the first half of 2024
- 23 Feb 2024 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) grants accelerated assessment for the upcoming Marketing Authorization Application (MAA) for VRC CHKVLP059 00 VP
- 30 Aug 2023 Emergent BioSolutions initiates a phase III trial in Chikungunya virus infections (Prevention) in USA (NCT06007183)